The Future of Health Technology Assessment (HTA) in Greece: Trends and Predictions

By Staff Writer

October 22, 2023

Greek Healthcare System

The Greek healthcare system is a unique blend of both public and private sectors. The National Organisation for the Provision of Health Services (EOPYY), established in 2011, is the sole purchaser of healthcare services for patients covered by the publicly financed National Health System (ESY). The Ministry of Health (MoH) is responsible for planning and regulating the ESY, and setting up regional health authorities (YPEs) that carry out extensive healthcare planning, organisation, and provision.

The introduction of the HTA framework in Greece in 2018 was a significant step forward towards evidence-based resource allocation decisions. It has improved patient access to innovative therapies at affordable prices and in a timely manner. Since its establishment, a significant improvement in the performance of the HTA process has been observed. The backlog of medicinal products has decreased, as well as the time of HTA clinical assessment.

However, the current HTA process in Greece does not include medical devices. This creates significant uncertainty for the providers of medical devices and pharmaceutical companies. A Committee for the Negotiation of Medical Devices’ Fees and Prices does exist, but it is not involved in the assessment of new technologies. It only negotiates the prices of technologies that either already exist in the market or are imported through ad hoc decisions.

There is strong consensus that the creation of a national decisive and legally binding HTA organisation, which will be independent of the MoH, both administratively and financially, might be more credible and effective. Another next step would be the inclusion of assessment and negotiation procedures for medical devices under an HTA organisation. This would help streamline the process and increase efficiency in the healthcare system.

Reference url

Recent Posts

suzetrigine pain management
      

Journavx for Pain Management: Toward Affordability and Access

💊 The jury is out on the pricing for Journavx®

Delve into our review of the recent ICER 2025 report on suzetrigine (Journavx®) to learn about the anticipated value relative to its clinical efficacy, safety profile and potential cost savings in tackling acute pain while addressing the opioid crisis.

Explore how suzetrigine paves the way for a safer, more effective approach to pain management and its implications on healthcare economics.

#SyenzaNews #HealthEconomics #HealthcareInnovation #Journavx

defunding scientific research
      

Defunding Scientific Research: Implications and Misconceptions in Gawande’s Analysis of Harvard Funding Cuts

🚨 What happens when scientific research funding is threatened?

In his thought-provoking article, Atul Gawande highlights the dire implications of proposed federal funding cuts to elite institutions like Harvard. He argues that such actions could devastate not just innovation, but also patient care and public health across the nation.

Explore the complexities of research funding and the potential ripple effects on America’s scientific landscape. Don’t miss out on these critical insights!

#SyenzaNews #HealthcareInnovation #HealthEconomics #MarketAccess

perioperative immunotherapy bladder cancer
       

FDA Approves Perioperative Immunotherapy for Bladder Cancer: A Breakthrough in MIBC Treatment

🚀 Are we witnessing a new era in bladder cancer treatment?

The FDA’s recent approval of durvalumab as the first perioperative immunotherapy for muscle-invasive bladder cancer (MIBC) could revolutionize outcomes for patients facing this formidable diagnosis. With significant improvements in event-free survival and overall survival over standard chemotherapy, this groundbreaking treatment offers new hope 🎉.

Curious about how this could shape the future of cancer care? Dive into the full article to uncover the potential impacts on clinical practice and health economics.

#SyenzaNews #oncology #HealthEconomics

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.